Clinical trial
Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes
NCT02265809 · Cambridge University Hospitals NHS Foundation Trust, Other · Completed
Key facts
| NCT number | NCT02265809 |
|---|---|
| Title | Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes |
| Official title | Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes (DILfrequency) |
| Acronym | DILfrequency |
| Lead sponsor | Cambridge University Hospitals NHS Foundation Trust, Other |
| Collaborators | University of Cambridge Sir Jules Thorn Charitable Trust Juvenile Diabetes Research Foundation Wellcome Trust National Institute for Health Research, United Kingdom |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Type 1 Diabetes |
| Intervention type | Drug |
| Interventions | Aldesleukin |
| Enrollment | 41 |
| Start date | Oct 3, 2014 |
| Primary completion | May 26, 2016 |
| Completion | May 26, 2016 |
| First posted | Oct 16, 2014 |
| Last update posted | Aug 21, 2018 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: